3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Polycystic Ovary Syndrome
139
Breast Neoplasms
31
Prostatic Neoplasms
29
Insulin Resistance
28
Obesity
19
Pancreatic Neoplasms
13
Neoplasms
12
Infertility
12
Endometrial Neoplasms
12
Carcinoma, Non-Small-Cell Lung
12
Colorectal Neoplasms
11
Anovulation
9
Lung Neoplasms
8
Metabolic Syndrome
7
Melanoma
7
Hyperandrogenism
7
Glioblastoma
7
Diabetes Mellitus
7
Squamous Cell Carcinoma of Head and Neck
6
Neoplasm Metastasis
6
Rectal Neoplasms
5
Adenocarcinoma
5
Weight Loss
4
Urinary Bladder Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Head and Neck Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Adenocarcinoma of Lung
4
Uterine Cervical Neoplasms
3
Recurrence
3
Interventions
Cyclophosphamide
297
Rituximab
272
Etoposide
149
Filgrastim
142
fludarabine phosphate
120
Cytarabine
109
Vincristine
107
Melphalan
102
Radiotherapy
101
Doxorubicin
97
Peripheral Blood Stem Cell Transplantation
93
Methotrexate
91
fludarabine
86
Prednisone
86
Busulfan
86
Tacrolimus
66
Mycophenolic Acid
62
Granulocyte Colony-Stimulating Factor
60
Antilymphocyte Serum
58
Dexamethasone
57
Whole-Body Irradiation
55
Carmustine
54
Bortezomib
45
Cyclosporine
44
Lenalidomide
41
Methylprednisolone
40
sargramostim
39
Bendamustine Hydrochloride
37
ibritumomab tiuxetan
34
Ifosfamide
34
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoma
×
Metformin
×
Clear all
NCT02531308
2022-09-28
DLBCL
Rush University Medical Center
Phase 2
Terminated
5 enrolled
5 charts